FTC Gets Injunction Against Predatory Publisher

FTC LogoAccording to a recent report on Retraction Watch, one day after OrthoBuzz posted an article about predatory publishers, a federal court ordered Srinubabu Gedela, CEO of OMICS Group and two sister companies, to stop what the Federal Trade Commission (FTC) said in an August 2016 lawsuit were deceptive business practices related to journal publishing. On its website, OMICS claims to publish “700+ open access journals.”

In issuing the preliminary injunction, US District Court Judge Gloria Navarro found evidence supporting the FTC’s claims that OMICS misled readers about whether articles had been peer-reviewed, hid publishing fees until after papers had been accepted, and presented misleading impact-factor data.

Under the preliminary injunction, OMICS will still be able to publish journals; the injunction relates only to specific “misrepresentations.” Gregory Ashe, a senior attorney at the FTC, told Retraction Watch that “nothing in this order goes to what [OMICS] can or can’t publish in terms of content. This is about how they are soliciting would-be academics to publish in their journals.”

If the FTC learns from academic consumers that OMICS is violating this injunction, the commission would then have to file a contempt-of-court motion. If you feel you have been victimized by unfair or deceptive business practices in academic publishing, you can contact the FTC’s Consumer Response Center at 1-877-382-4357.

Jason Miller, JBJS Executive Publisher
Lloyd Resnick, JBJS Developmental Editor

Patient Satisfaction After ACL Reconstruction—Dec. 13 Webinar

webinar speakersWe still have many unanswered questions about patient satisfaction after anterior cruciate ligament (ACL) reconstruction.

  • Do specific patient populations benefit from more or fewer physical therapy (PT) visits?
  • Does the cost of PT affect patient satisfaction?
  • Should patients be classified by factors beyond their medical diagnoses to achieve the best outcomes while minimizing costs?
  • What are the rates and predictors of return to play after ACL reconstruction? Does graft choice play a role?
  • What is the relationship between return to play and patient satisfaction?

On Wednesday, December 13, 2017 at 8:00 PM EST, the Journal of Orthopaedic & Sports Physical Therapy (JOSPT) and The Journal of Bone & Joint Surgery (JBJS) will host a complimentary* LIVE webinar that addresses these important and clinically applicable questions.

JOSPT co-author Caitlin J. Miller, PT, DPT, will share the results of a retrospective cohort study examining the relationship between patient demographics, number of physical therapy visits, and the cost of postoperative interventions with revision rates and patient-reported outcomes following primary ACL reconstruction.

JBJS co-author Benedict U. Nawachukwu, MD, MBA, will discuss findings from a study  of return to play and patient satisfaction among athletes following ACL reconstruction. This study also explores the efficacy of patellar tendon autografts and the preinjury impact of certain sports.

Moderated by Tara Jo Manal, PT, DPT, OCS, SCS, FAPTA, a leading authority on the spine and the knee, the webinar will include additional insights from expert commentators Mark V. Paterno, PT, PhD, MBA, SCS, ATC, and Elizabeth Matzkin, MD. The last 15 minutes will be devoted to a live Q&A session between the audience and panelists.

Seats are limited so REGISTER NOW.

*All registrants will have free access to the webinar for 24 hours following the live broadcast.

Fructosamine Bests HbA1c for Preop Glycemic Screening

Fructosamine for OBuzzPatients with diabetes have an increased risk of postoperative complications following total joint arthroplasty (TJA). Additionally, perioperative hyperglycemia has been identified as a common and independent risk factor for periprosthetic joint infection, even among patients without diabetes. Therefore, knowing a patient’s glycemic status prior to surgery is very helpful.

In the November 15, 2017 edition of The Journal of Bone & Joint Surgery, Shohat et al. demonstrate that serum fructosamine, a measure of glycemic control obtainable via a simple and inexpensive blood test, is a good predictor of adverse outcomes among TJA patients—whether or not they have diabetes.

Researchers screened 829 patients undergoing TJA for serum fructosamine and HbA1c—a common measure, levels of which <7% are typically considered good glycemic control. Patients with fructosamine levels ≥292 µmol/L had a significantly higher risk of postoperative deep infection, readmission, and reoperation, while HbA1c levels ≥7% showed no significant correlations with any of those three adverse outcomes. Among the 51 patients who had fructosamine levels ≥292 µmol/L, 39% did not have HbA1c levels ≥7%, and 35% did not have diabetes.

In addition to being more predictive of postsurgical complications than HbA1c, fructosamine is also a more practical measurement. A high HbA1c level during preop screening could mean postponing surgery for 2 to 3 months, while the patient waits to see whether HbA1c levels come down. Fructosamine levels, on the other hand, change within 14 to 21 days, so patients could be reassessed for glycemic control after only 2 or 3 weeks.

While conceding that the ≥292 µmol/L threshold for fructosamine suggested in this study should not be etched in stone, the authors conclude that “fructosamine could serve as the screening marker of choice” for presurgical glycemic assessment. However, because the study did not examine whether correcting fructosamine levels leads to reduced postoperative complications, a prospective clinical trial to answer that question is needed.

High Value Joint Replacements at Physician-Owned Hospitals

H image for OBuzzIn the November 15, 2017 issue of The Journal, Courtney et al. carefully evaluate CMS data to compare TKA and THA costs, complications, and patient satisfaction between physician-owned and non-physician-owned hospitals. The authors used risk-adjusted data when comparing complication scores between the two hospital types, in an attempt to address the oft-rendered claim that surgeons at physician-owned facilities “cherry pick” the healthiest patients and operate on the highest-risk patients in non-physician-owned facilities.

In general, the findings suggest that, for TKA and THA, physician-owned hospitals are associated with lower costs to Medicare, fewer complications and readmissions, and superior patient-satisfaction scores compared with non-physician-owned hospitals. These findings should come as no surprise to readers of The Journal. One fundamental principle of health care finance is that physicians control 70% to 80% of the total cost of care with their direct decisions. When physician incentives are aligned with those related to the facility, the result is better care at lower cost.

Nevertheless, many policymakers remain convinced that physician-owners are completely mercenary and base every decision on maximizing profit margins—even if that includes ordering unnecessary tests, performing unnecessary procedures, or using inferior implants. We need more transparency among physician-owners at local and national levels to address these usually-erroneous assumptions, which are frequently repeated by local non-physician-owned health systems. For example, we should be transparent with the percentage of the margin that ends up in the physician-owner’s pocket. Whatever the “right” percentage is, I believe it should not be the dominant factor in a physician’s total income..

The findings from Courtney et al. should spur further debate on this issue. I am confident that the best outcomes for individual patients and the public result when physicians (and their patients) stay in direct control of decision making regarding care, when surgeons are appropriately motivated to be cost- and outcome-effective, and when we all do our part to care for the under- and uninsured.

Marc Swiontkowski, MD
JBJS Editor-in-Chief

What’s New in Shoulder and Elbow Surgery 2017

Shoulder & elbowEvery month, JBJS publishes a Specialty Update—a review of the most pertinent and impactful studies published in the orthopaedic literature during the previous year in 13 subspecialties. Click here for a collection of all OrthoBuzz Specialty Update summaries.

This month, Aaron Chamberlain, MD, co-author of the October 18, 2017 Specialty Update on shoulder and elbow surgery, selected the most clinically compelling findings from among the 36 studies summarized in the Specialty Update.

Reverse Shoulder Arthroplasty
With reverse shoulder arthroplasty, surgeons often have difficulty setting expectations for patients due to the lack of long-term outcomes data. Bacle et al. published a study that describes the clinical outcomes in patients with at least 10 years’ follow-up. Medium-term outcomes among  an original cohort of 186 patients had been previously described. Eighty-four of those original patients were available for a mean long-term follow-up of 150 months. The mean overall Constant score fell from 63 at medium-term follow-up to 55 at final follow-up.  Active anterior elevation also decreased from 138° to 131.° Despite the decrease in Constant score and ROM between mid- and long-term follow-up, these two measures remained significantly better than preoperative values. Analysis showed a 93% implant survival probability at 120 months. This study will help surgeons counsel patients regarding long-term expectations after reverse shoulder arthroplasty – especially as younger patients are increasingly indicated for this procedure.

Rotator Cuff Repair
A central focus of studies evaluating rotator cuff repair has been to better understand the biological environment that influences tendon healing. Greater understanding of the genetic influence in rotator cuff pathology may lead to interventions that could improve the healing environment.  Tashjian et al. reported outcomes after arthroscopic rotator cuff repair in 72 patients who were assessed for family history of rotator cuff tears and underwent a genetic analysis looking for variants in the estrogen-related receptor beta (ESRRB) gene.1 Positive family history and tear retraction were associated with a failure of healing, and lateral tendon retears were associated with both family history and the presence of a single nucleotide polymorphism in the ESRRB gene.

In another recent study focused on the biological healing environment after rotator cuff repair, a prospective randomized trial of platelet-rich plasma (PRP) in patients undergoing repair of a medium to large-sized rotator cuff tear2 found that patients who received PRP experienced an increase in vascularity at the repair site up to 3 months postoperatively. The PRP group also demonstrated better Constant-Murley and UCLA scores and lower retear rates than the no-PRP group, but there was no difference in ASES scores. In another recent randomized trial, 120 patients were randomized to either PRP or ropivacaine injection after rotator cuff repair.3 No between-group differences in clinical outcome scores or retear rates were identified. The contrasting results of these two recent randomized studies illustrate the challenge of identifying any conclusive benefit of PRP in the setting of rotator cuff repair.

Prosthetic Shoulder Infection
Accurate diagnosis of prosthetic shoulder infection continues to present a formidable challenge, given the difficulty of detecting Proprionibacterium acnes (P. acnes) and interpreting when positive results are clinically significant. Development of P. acnes tests that are more rapid and precise in identifying clinically significant infections would be of significant value.  Holmes et al. evaluated a PCR restriction fragment length polymorphism (RFLP) technique to identify P. acnes from infected tissue in the shoulder.4 In this study, within 24 hours of sampling, the PCR-RFLP assay detected P. acnes-specific amplicons in as few as 10 bacterial cells.

Clavicle Fractures
Approaches to managing clavicle fractures have evolved significantly over the past several decades. While it was once generally accepted that middle third clavicle fractures should be managed nonoperatively, multiple studies have described concerning rates of nonunions and symptomatic malunions. A multicenter prospective trial that randomized patients to either surgical fixation with a plate or nonoperative management identified a nonunion rate of 23.1% in the nonoperatively managed group, compared with a 2.4% nonunion rate in the surgically treated group (p<0.0001). However, the rate of secondary operations was 27.4% in the operatively treated group (most for plate removal) versus 17.1% in the nonoperative group, although that difference did not reach statistical significance (p=0.18). These results will help inform discussions between providers and patients when considering management options for midshaft clavicle fractures.

References

  1. Tashjian RZ, Granger EK, Zhang Y, Teerlink CC, Cannon-Albright LA. Identification of a genetic variant associated with rotator cuff repair healing. J Shoulder Elb Surg. 2016. doi:10.1016/j.jse.2016.02.019.
  2. Pandey V, Bandi A, Madi S, et al. Does application of moderately concentrated platelet-rich plasma improve clinical and structural outcome after arthroscopic repair of medium-sized to large rotator cuff tear? A randomized controlled trial. J Shoulder Elb Surg. 2016;26(3):e82-e83. doi:10.1016/j.jse.2016.01.036.
  3. Flury M, Rickenbacher D, Schwyzer H-K, et al. Does Pure Platelet-Rich Plasma Affect Postoperative Clinical Outcomes After Arthroscopic Rotator Cuff Repair? Am J Sports Med. 2016. doi:10.1177/0363546516645518.
  4. Holmes S, Pena Diaz AM, Athwal GS, Faber KJ, O’Gorman DB. Neer Award 2017: A rapid method for detecting Propionibacterium acnes in surgical biopsy specimens from the shoulder. J Shoulder Elb Surg. 2017. doi:10.1016/j.jse.2016.10.001.

JBJS Case Connector to Be Indexed in MEDLINE/PubMed

JBJS_PL_Case_Connector_RGBThe National Library of Medicine has accepted JBJS Case Connector for indexing in MEDLINE/PubMed.

Launched in July 2011 and co-edited by Thomas W. Bauer, MD and Ronald W. Lindsey, MD, JBJS Case Connector compiles thousands of orthopaedic case reports, empowering surgeons to find cases similar to theirs, to identify emerging trends, and to distinguish between truly rare cases and repeated, related instances of a larger problem. Using this unique online journal, surgeons can find the commonalities between cases and filter case information by many important variables to provide the best possible care for orthopaedic patients.

In addition, monthly “Case Connections” essays explore the clinical relationships between recent articles and prior case reports in the wider orthopaedic literature, helping surgeons to identify potential patterns. And JBJS Case Connector Image Quizzes” provide interactive challenges based on JBJS case-report images, featuring in-depth discussions of relevant ideas and concepts.

If you are not already a JBJS Case Connector subscriber, click here to learn more.

Jason Miller
Executive Publisher

New Hope for New Bone After Osteomyelitis Debridement

Osteomyelitis Tibia for OBuzzThis basic science tip comes from Fred Nelson, MD, an orthopaedic surgeon in the Department of Orthopedics at Henry Ford Hospital and a clinical associate professor at Wayne State Medical School. Some of Dr. Nelson’s tips go out weekly to more than 3,000 members of the Orthopaedic Research Society (ORS), and all are distributed to more than 30 orthopaedic residency programs. Those not sent to the ORS are periodically reposted in OrthoBuzz with the permission of Dr. Nelson.

One clinical frustration following osteomyelitis debridement is poor bone healing. Impaired bone homeostasis provokes serious variations in bone remodeling that involve multiple inflammatory cytokines.

The chemokines CCL2, CCL3, and CXCL2 are known to be strong chemoattractants for neutrophils during inflammatory states, and they play a role during osteoclastogenesis. B cells are also activators of osteoclastognesis and are regulated, in part, by tissue inhibitor of metalloprotease 1 (TIMP-1).

Researchers drilled a 1 mm hole into the proximal tibia of 126 mice. In half of the mice (63), a dose of S. aureus was injected into the canal, while the controls had no bacteria injected. At two weeks, all proximal tibiae were debrided; cultures were taken 3 and 7 days after debridement to assure no residual infection. Cytokine assays and Western blots for CCL2, CCL3, CXCL2, TIMP-1, RANKL, and TNF-α were performed in selected mice in each group. Flow cytometry and histology were also done in selected mice in each group.

In the osteomyelitis group, Western blot analysis identified increased levels of CCL2, CCL3, and CXCL2. Histology revealed increased osteoclastogenesis after osteomyelitis debridement, with calcitonin-receptor and RANKL detection via immunohistochemical and fluorescence staining. There was diminished osteogenesis and proliferation in the osteomyelitis group, but TNF-α expression seemed to have no effect on altered bone regeneration after bone infection. Flow cytometry revealed elevated B cell activity in the osteomyelitis group, with subsequent increased osteoclast activity and accelerated bone resorption.

The researchers propose a RANKL-dependent osteoclastogenesis after debridement for osteomyelitis that is associated with elevated B cells and decreased osteogenesis. These findings could lead to new interventions to improve bone healing during the course of osteomyelitis treatment, particularly following debridement.

Reference
Wagner JM, Jaurich H, Wallner C, Abraham S, Becerikli M, Dadras M, Harati K, Duhan V, Khairnar V, Lehnhardt M, Behr B. Diminished bone regeneration after debridement of posttraumatic osteomyelitis is accompanied by altered cytokine levels, elevated B cell activity, and increased osteoclast activity. J Orthop Res. 2017 Mar 6. doi: 10.1002/jor.23555. [Epub ahead of print] PMID: 28263017

Certain Comorbidities Boost Risk of Acute Kidney Injury after THA

AKI Risk for OBuzzThe relationship between chronic kidney disease (CKD) and acute kidney injury (AKI) is circular: surgical patients with preexisting CKD are at increased risk of AKI, and even mild or transient AKI is associated with future development of CKD.

In the November 1, 2017 JBJS, Gharaibeh et al. report findings from a retrospective cohort study with a nested case-control analysis that assessed the rate and risk factors associated with AKI after total hip arthroplasty (THA).

From a total of 10,323 THAs analyzed, AKI developed postoperatively in only 114 cases (1.1%). A multivariate analysis of the entire cohort identified four preoperative comorbidities that increased the risk of AKI by 2- to 4-fold: CKD, heart failure, diabetes, and hypertension. In addition to those risk factors, an analysis of the case-control cohort found that increasing BMI and perioperative blood transfusions were also associated with a higher risk of AKI.

Using data from the entire cohort, the authors developed an AKI risk calculator focused on presurgical variables (see graph). Based on that model, which will require independent validation, a 65-year-old man with either CKD or heart failure would have a 2% risk of AKI; the risk would increase to 4% if that patient had CKD and hypertension and to 16.1% in the presence of CKD, hypertension, and heart failure.

The anticipated increase in demand for joint replacements could lead to US surgeons performing approximately 572,000 THAs during the year 2030. A certain (and possibly increasing) proportion of those future procedures will occur in patients who have hypertension, diabetes, heart failure, and/or chronic kidney disease. The findings from Gharaibeh et al., especially the yet-to-be-validated AKI risk score, could help hip surgeons better counsel patients and identify those who might benefit from heightened postsurgical monitoring of kidney function.

Nov. 15 Webinar—Treating Clavicle Fractures

Capture_Clavicle FX for OBuzzOn November 15, 2017 at 7 PM EDTJBJS will join with JSES (Journal of Shoulder and Elbow Surgery) to present a webinar looking at the current paradigm for treating  clavicle fractures. Co-moderated by Drs. William Mallon, editor-in-chief of JSES, and Andrew Green, deputy editor of JBJS, the webinar will focus on two recent clavicle-fracture papers:

  • Dr. Philip Ahrens will discuss his recent JBJS paper, “The Clavicle Trial: A Multicenter Randomized Controlled Trial Comparing Operative with Nonoperative Treatment of Displaced Midshaft Clavicle Fractures.”
  • Dr. Brian Feeley will discuss his 2016 JSES paper, “Plate Fixation of Midshaft Clavicular Fractures: Patient-Reported Outcomes and Hardware-Related Complications.”

After each author presentation, expert commentary will be provided. Discussing Dr. Ahrens’ paper will be Dr. Michael McKee, recently named chairman of orthopaedics at the University of Arizona. Dr. Gus Mazzocca, chairman of orthopaedics at the University of Connecticut, will comment on Dr. Feeley’s paper. The webinar will then be open to addressing viewer-submitted questions for the authors and the commentators.

Seats are limited, so register now!